1.46

2.82% 0.04

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $1.46, with a volume of 1.18M. It is up +2.82% in the last 24 hours and down -7.01% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$1.42

Open:

$1.46

24h Volume:

1.18M

Relative Volume:

0.96

Market Cap:

$363.98M

Revenue:

$14.56M

Net Income/Loss:

$-63.37M

P/E Ratio:

-5.2461

EPS:

-0.2783

Net Cash Flow:

$-19.44M

1W Performance:

-6.41%

1M Performance:

-7.01%

6M Performance:

-19.78%

1Y Performance:

+218.43%

1-Day Range:

$1.45

$1.50

1-Week Range:

$1.40

$1.58

52-Week Range:

$0.425

$2.09

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2026-05-12

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	1.46	363.98M	14.56M	-63.37M	-19.44M	-0.2783
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

May 05, 2026

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update - PharmiWeb.com

May 05, 2026

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Weekly Voice

May 05, 2026

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) - Weekly Voice

May 05, 2026

May 04, 2026

Lineage Cell Therapeutics Price Target Maintained With a $3.00/Share by D. Boral Capital - Moomoo

May 04, 2026

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital - Moomoo

May 04, 2026

LCTX Maintained by D. Boral Capital -- Price Target at $3.00 - GuruFocus

May 04, 2026

Lineage Cell Therapeutics presents 3-year Phase 1-2a OpRegen trial results in geographic atrophy at summit - Traders Union

May 04, 2026

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 - Investing News Network

May 04, 2026

3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 - Business Wire

May 04, 2026

Apr 29, 2026

[ARS] Lineage Cell Therapeutics, Inc. SEC Filing - Stock Titan

Apr 29, 2026

Lineage Cell Therapeutics (NYSE American: LCTX) sets 2026 vote on directors, auditor and executive pay - Stock Titan

Apr 29, 2026

Apr 28, 2026

LCTX Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus

Apr 28, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat

Apr 28, 2026

Canaccord Genuity initiates coverage of Lineage Cell Therapeutics (LCTX) with buy recommendation - MSN

Apr 28, 2026

Apr 20, 2026

Lineage (LCTX) Stock Hot Topic (Risk Aversion) 2026-04-20Revenue Growth Stocks - Xã Châu Thành

Apr 20, 2026

Apr 15, 2026

Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration - simplywall.st

Apr 15, 2026

Apr 14, 2026

Lineage Announces Formation of Scientific Advisory Board - BioSpace

Apr 14, 2026

Apr 13, 2026

Lineage Cell Therapeutics (LCTX) Establishes New Scientific Advi - GuruFocus

Apr 13, 2026

Lineage Cell Therapeutics forms advisory board, names clinical head By Investing.com - Investing.com Australia

Apr 13, 2026

Lineage Cell Therapeutics forms advisory board, names clinical head - Investing.com

Apr 13, 2026

Apr 12, 2026

Guidance Update: Can Lineage Cell Therapeutics Inc maintain sales growth2026 Market Trends & Reliable Intraday Trade Alerts - baoquankhu1.vn

Apr 12, 2026

Apr 11, 2026

Tech Rally: Is Lineage Cell Therapeutics Inc still a buy after recent gains2026 Stock Rankings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn

Apr 11, 2026

If You Invested $1,000 in Lineage Cell The (LCTX) - Stock Titan

Apr 11, 2026

Apr 10, 2026

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Finansavisen

Apr 10, 2026

Will Lineage (LCTX) Stock Recover Soon | Price at $1.49, Down 0.34%Chart Patterns - Newser

Apr 10, 2026

Apr 09, 2026

Lineage Cell Therapeutics launches COR1 for corneal diseases amid rising FECD prevalence - Traders Union

Apr 09, 2026

Apr 08, 2026

Q4 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus

Apr 08, 2026

Apr 07, 2026

Pharma News: Can Lineage Cell Therapeutics Inc reach resistance levels soon2026 Technical Overview & AI Enhanced Trading Signals - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Is Lineage (LCTX) Stock Testing Resistance | Price at $1.58, Up 0.64%Investment Community Signals - Newser

Apr 06, 2026

Apr 05, 2026

Lineage Cell Therapeutics pushes scalable platforms to address drug discovery complexity - Traders Union

Apr 02, 2026

Apr 01, 2026